Sandoz Group AG
SDZ | SW
Overview
Corporate Details
- ISIN(s):
- CH1243598427 (+2 more)
- LEI:
- 5493000JWK6XWFEUD320
- Country:
- Switzerland
- Address:
- Suurstoffi 14, 6343 Rotkreuz
- Website:
- http://www.sandoz.com
- Sector:
- Health Care
- Industry:
- Health Care Providers & Services
Description
Sandoz operates in the attractive and growing global off-patent medicines market, which benefits from a growing and aging population, higher rates of chronic disease, increasing market adoption as healthcare systems and payors seek to reduce the cost of medicines, and a consistent supply of upcoming loss of exclusivities (LoEs) as patents for originator products expire. Together, these drivers are expected to support long-term growth in volumes that will more than offset anticipated erosion in price.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-01 02:00 |
Regulatory News Service
Sandoz further asserts leadership in biosimilars, breaking ground on new Sloven…
|
English | 7.7 KB | |
| 2025-06-02 02:00 |
Regulatory News Service
Sandoz launches first and only interchangeable denosumab biosimilars in US, pro…
|
English | 19.9 KB | |
| 2025-05-21 02:00 |
Regulatory News Service
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe …
|
English | 10.8 KB | |
| 2025-03-05 01:00 |
Earnings Release
Sandoz reports strong FY 2024 results and Q4 2024 sales
|
English | 83.1 KB | |
| 2025-02-24 01:00 |
Regulatory News Service
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new…
|
English | 21.0 KB | |
| 2025-02-03 01:00 |
Board/Management Change
Francisco Ballester to retire; Peter Stenico appointed President Region Interna…
|
English | 5.4 KB | |
| 2025-01-14 01:00 |
Earnings Release
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd An…
|
English | 11.2 KB | |
| 2024-12-17 01:00 |
Inside Information Statement
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Ac…
|
English | 7.6 KB | |
| 2024-11-15 01:00 |
Regulatory News Service
Sandoz receives European Commission approval for Afqlir® (aflibercept), further…
|
English | 7.2 KB | |
| 2024-10-30 01:00 |
Earnings Release
Sandoz reports third-quarter and nine-month 2024 sales
|
English | 32.6 KB | |
| 2024-08-12 02:00 |
Regulatory News Service
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthe…
|
English | 9.9 KB | |
| 2024-08-08 02:00 |
Earnings Release
Sandoz reports second-quarter sales and half-year 2024 results
|
English | 53.6 KB | |
| 2024-07-25 02:00 |
Regulatory News Service
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chro…
|
English | 7.3 KB | |
| 2024-07-01 02:00 |
Regulatory News Service
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by S…
|
English | 12.2 KB | |
| 2024-05-22 02:00 |
Regulatory News Service
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the firs…
|
English | 9.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-02 | N/A | Non-Executive member | Buy | None | 251,343.62 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 270,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 260,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 230,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 202,500.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 187,500.00 CHF |
| 2024-08-21 | N/A | Non-Executive member | Buy | None | 429,855.85 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 130,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 115,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 62,500.00 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANGLING DIRECT PLC | United Kingdom | ANG | |
|
ANGLO ASIAN MINING PLC | Azerbaijan | AAZ | |
|
Athens Medical C.S.A. | Greece | IATR | |
|
Bastide Le Confort Médical | France | BLC | |
|
Biocartis Group NV | Belgium | BCART | |
|
Braster S.A. | Poland | BRA | |
|
Cannabis Poland Spolka Akcyjna | Poland | CBD | |
|
Carasent | Norway | CARA | |
|
Center for Genetics and Reproductive Medicine "GENETICO" | Russian Federation | GECO | |
|
Clinica Baviera S.A. | Spain | CBAV |